术后鼻咽血管纤维瘤放射性核素显像研究(PARIS)方案的前列腺特异性膜抗原PET/CT验证
这项前瞻性研究纳入22例术前和术后均接受PSMA PET/CT检查的术后青少年鼻咽血管纤维瘤(JNA)患者,以PSMA PET/CT为影像学标准评估残留病灶。对比增强MRI(CEMRI)诊断残留病灶的灵敏度、特异度、阳性预测值和阴性预测值分别为100%、53.33%、41.67%和100%,PSMA PET/CT上述参数均为100%。结论认为CEMRI过于敏感且特异度较低,应始终采用PARIS方案。
要点
- 术后JNA残留/复发诊断中,CEMRI特异度仅53.33%、阳性预测值41.67%,存在过度诊断。
- PSMA PET/CT诊断残留病灶的灵敏度、特异度、阳性预测值和阴性预测值均为100%。
- PSMA PET/CT在肿瘤范围勾画、决策制定和立体定向放疗计划方面优于CEMRI。
核心结论
- CEMRI相比PSMA PET/CT过于敏感且特异度较低,术后应始终采用PARIS方案。
- PSMA PET/CT在残留肿瘤诊断、肿瘤勾画、决策制定、立体定向放疗计划和随访辅助方面具有明显优势。
研究设计与样本
- 前瞻性研究纳入22例2018年1月至2020年9月期间术前和术后均接受PSMA PET/CT检查的术后JNA患者。
- 所有患者接受低剂量头颈部局部PET/CT显像。
- 以PSMA PET/CT findings作为影像学标准,并据此管理患者。
主要发现
- 术后CEMRI评估显示12例有残留肿瘤、2例正常但可疑、8例术后扫描正常。
- PSMA PET/CT显示仅7例有残留肿瘤、15例术后扫描正常。
- 1例两种扫描均显示残留肿瘤的患者中,肿瘤范围存在差异,PSMA PET/CT准确勾画了肿瘤。
关键数值与推荐
- CEMRI诊断残留病灶的灵敏度、特异度、阳性预测值和阴性预测值分别为100%、53.33%、41.67%和100%。
- PSMA PET/CT诊断残留病灶的灵敏度、特异度、阳性预测值和阴性预测值均为100%。
临床怎么用
- 术后JNA患者应采用PARIS方案行PSMA PET/CT,以更准确检测或排除残留/复发肿瘤。
- PSMA PET/CT可用于残留肿瘤的肿瘤勾画、治疗决策、立体定向放疗计划及未来随访辅助。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Juvenile nasopharyngeal angiofibroma (JNA) expresses prostate-specific membrane antigen (PSMA), and PSMA PET/CT scan may be used for its imaging. Also, the precise diagnosis of residual/recurrent JNA after surgical treatment remains difficult with conventional contrast MRI and/or CT; functional imaging with PSMA PET/CT promises greater accuracy in the detection or exclusion of recurrent/residual JNA. PATIENTS AND METHODS: In this prospective study, 22 postoperative JNA patients who underwent a PSMA PET/CT scan both preoperatively and postoperatively from January 2018 to September 2020 were included. All patients underwent a low-dose head and neck spot PET/CT imaging. Abnormal postcontrast enhancement of a definite lesion was considered residual/recurrent tumor in contrast-enhanced MRI (CEMRI). In PSMA PET/CT, any abnormal uptake apart from physiological sites in the head and neck was considered as residual lesions. Radiological results were categorized as negative, suspicious for residual lesions, or definite residual/recurrent tumors. PSMA PET/CT findings were considered as the radiological standard, and patients were managed accordingly. The sensitivity, specificity, positive predictive value, and negative predictive value were separately calculated for CEMRI and PSMA PET/CT for diagnosing residual lesions. RESULTS: On postoperative CEMRI evaluation, 12 patients had residual tumors, 2 had normal suspicious scans, and 8 had normal postoperative scans. On PSMA PET/CT, only 7 patients had residual tumors and 15 had normal postoperative scans. In 1 patient with a residual tumor on both scans, a discrepancy was noted concerning tumor extent, and PSMA PET/CT accurately mapped the tumor. The sensitivity, specificity, positive predictive value, and negative predictive value of CEMRI were 100%, 53.33%, 41.67%, and 100%, respectively. The sensitivity, specificity, positive predictive value, and negative predictive value of PSMA PET/CT were 100% for all parameters. CONCLUSIONS: Because CEMRI is oversensitive and less specific compared with PSMA PET/CT, Postoperative Angiofibroma Radionuclide Imaging Study (PARIS) protocol should be used always. In residual tumors, PSMA PET/CT has an outright advantage over CEMRI in the diagnosis, tumor mapping, decision making, planning stereotactic radiation, and aiding in future follow-ups.
引用
- Thakar A, Sakthivel P, Thankarajan Arunraj S, et al. Validation of Postoperative Angiofibroma Radionuclide Imaging Study (PARIS) Protocol Using PSMA PET/CT-A Proof of Concept Study. Clin Nucl Med. 2021. PMID: 33630789. doi:10.1097/RLU.0000000000003516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。